Abstract
AIB1 (amplified in breast cancer 1) is a nuclear receptor coactivator gene amplified and overexpressed in breast cancer. However, the mechanisms by which AIB1 is regulated are unclear. Here we show that 17β-estradiol represses AIB1 mRNA and protein expression in MCF-7 human breast cancer cells primarily by suppressing AIB1 gene transcription. Estrogen levels present in fetal calf serum are sufficient to maintain AIB1 mRNA and protein at low basal levels, and this repression is reversed by the addition of antiestrogens or all-trans retinoic acid. Interestingly, cycloheximide inhibition experiments revealed that secondary protein synthesis was necessary to induce AIB1 expression by antiestrogens and retinoids. Experiments with TGF-β and TGF-β blocking antibodies demonstrated that this growth factor modulates AIB1 expression and showed that the antiestrogen and retinoid induction of AIB1 gene expression is mediated at least in part through TGF-β. These data reveal a mechanism of estrogen-induced down-modulation of the overall hormone sensitivity of cells through feedback inhibition of coactivator gene expression. These data also suggest that antiestrogens can shift the sensitivity of cells to non-estrogenic proliferative signaling by increasing cellular levels of AIB1. This effect may play a role in breast cancer progression and resistance to drug treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akiyama N, Matsuo Y, Sai H, Noda M, Kizaka-Kondoh S . 2000 Mol. Cell. Biol. 20: 3266–3273
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS . 1997 Science 277: 965–968
Bai J, Uehara Y, Montell DJ . 2001 Cell 103: 1047–1058
Bautista S, Valles H, Walker SL, Anzick S, Zellinger R, Meltzer P, Theillet C . 1998 Clin. Cancer Res. 4: 2925–2929
Belandia B, Parker MG . 2000 J. Biol. Chem. 275: 30801–30805
Bouras T, Southey MC, Venter DJ . 2001 Cancer Res. 61: 903–907
Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM . 1997a Cell 90: 569–580
Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM . 1997b Cell 90: 569–580
Choudhury A, Singh RK, Moniaux N, El-Metwally TH, Aubert JP, Batra SK . 2000 J. Biol. Chem. 275: 33929–33936
Degitz SJ, Morris D, Foley GL, Francis BM . 1998 Teratology 58: 197–204
Dumont N, Arteaga CL . 2000 Breast Cancer Res. 2: 125–132
Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR . 1998 Int. J. Cancer 75: 721–730
Ghadimi BM, Schrock E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Ried T . 1999 Am. J. Pathol. 154: 525–536
Guan XY, Xu J, Anzick SL, Zhang H, Trent JM, Meltzer PS . 1996 Cancer Res. 56: 3446–3450
Jakowlew SB, Zakowicz H, Moody TW . 2000 Peptides 21: 1831–1837
Karey KP, Sirbasku DA . 1988 Cancer Res. 48: 4083–4092
Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB . 1987 Cell 48: 417–428
Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG, Arteaga CL . 1997 J. Biol. Chem. 272: 8296–8302
Lee S-K, Kim H-J, Kim JW, Lee JW . 1999 Mol. Endocrinol. 13: 1924–1933
Li H, Chen JD . 1998 J. Biol. Chem. 273: 5948–5954
Li H, Gomes PJ, Chen JD . 1997 Proc. Natl. Acad. Sci. USA 94: 8479–8484
Lippman ME, Bolan G . 1975 Nature 256: 592–593
List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT . 2001a J. Biol. Chem. 276: 23763–23768
List HJ, Reiter R, Singh B, Wellstein A, Riegel AT . 2001b Breast Cancer Res. Treat. 68: 21–28
McKenna NJ, Lanz RB, O'Malley BW . 1999 Endocrine Rev. 20: 321–344
McKenna NJ, O'Malley BW . 2002 Cell 108: 465–474
Misiti S, Schomburg L, Yen PM, Chin WW . 1998 Endocrinology 139: 2493–2500
Nephew KP, Ray S, Hlaing M, Ahluwalia A, Wu SD, Long X, Hyder SM, Bigsby RM . 2000 Biol. Reprod. 63: 361–367
Oft M, Heider KH, Beug H . 1998 Curr. Biol. 8: 1243–1252
Onate SA, Tsai SY, Tsai M-J, O'Malley BW . 1995 Science 270: 1354–1357
Orlando V, Strutt H, Paro R . 1997 Methods 11: 205–214
Reiter R, Wellstein A, Riegel AT . 2001 J. Biol. Chem. 276: 39736–39741
Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, Kimura A, Nakamura Y, Inazawa J, Abe T, Yamagishi H . 2000 Int. J. Cancer 89: 217–223
Segars JH, Marks MS, Hirschfeld S, Driggers PH, Martinez E, Grippo JF, Wahli W, Ozato K . 1993 Mol. Cell. Biol. 13: 2258–2268
Suen C-S, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE . 1998 J. Biol. Chem. 273: 27645–27653
Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW . 1997 J. Biol. Chem. 272: 27629–27634
Vindelov LL, Christensen IJ, Nissen NI . 1983 Cytometry 3: 323–327
Voegel JJ, Heine MJS, Zechel C, Chambon P, Gronmeyer H . 1996 EMBO J. 15: 3667–3675
Walfish PG, Yoganathan T, Yang Y-F, Hong H, Butt TR, Stallcup MR . 1997 Proc. Natl. Acad. Sci. USA 94: 3697–3702
Wang D, Sun L, Zborowska E, Willson JK, Gong J, Verraraghavan J, Brattain MG . 1999 J. Biol. Chem. 274: 12840–12847
Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, Szeto D, Gleiberman A, Krones A, Pratt K, Rosenfeld R, Glass CK, Rosenfeld MG . 2000 Proc. Natl. Acad. Sci. USA 97: 13549–13554
Welch DR, Fabra A, Nakajima M . 1990 Proc. Natl. Acad. Sci. USA 87: 7678–7682
Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley BW . 2000 Proc. Natl. Acad. Sci. USA 97: 6379–6384
Yue J, Mulder KM . 2000 J. Biol. Chem. 275: 30765–30773
Acknowledgements
We thank Dr Ronald W Evans for the generous gift of the plasmid pRCMX-ACTR/A38. This work was supported by grants from the Breast Cancer Research Program of the Department of Defense, DAMD # 17-01-1-0249 (KJ Lauritsen) and DAMD # 17-99-1-9203 (AT Riegel).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lauritsen, K., List, HJ., Reiter, R. et al. A role for TGF-β in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 21, 7147–7155 (2002). https://doi.org/10.1038/sj.onc.1205943
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205943
Keywords
This article is cited by
-
The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ
Oncogene (2014)
-
Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
BMC Cancer (2012)
-
Expression of AIB1 protein as a prognostic factor in breast cancer
World Journal of Surgical Oncology (2011)
-
Progesterone and estradiol effects on SRC-1 and SRC-3 expression in human astrocytoma cell lines
Endocrine (2010)
-
Alternations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications
Medical Oncology (2010)